| Provenge (sipuleucel-T) / Bausch Health |
NCT00027599: APC8015 and Bevacizumab in Treating Patients With Prostate Cancer |
|
|
| Completed | 2 | 25 | US | bevacizumab, prostatic acid phosphatase-sargramostim fusion protein, sipuleucel-T, therapeutic autologous dendritic cells, in vitro-treated peripheral blood stem cell transplantation | National Cancer Institute (NCI) | Prostate Cancer | 07/07 | | | |
ProACT, NCT00715078: To Evaluate Sipuleucel-T Manufactured With Different Concentrations of (PA2024) Antigen |
|
|
| Completed | 2 | 122 | US | sipuleucel-T | Dendreon | Prostate Cancer | 04/12 | 05/15 | | |
| Completed | 2 | 42 | US | Sipuleucel-T with Booster, Sipuleucel-T without Booster | Dendreon, University of California, San Francisco | Prostate Cancer | 12/12 | 12/13 | | |
| Completed | 2 | 47 | Europe | sipuleucel-T, PROVENGE, APC8015 | Dendreon | Cancer of Prostate, Cancer of the Prostate, Neoplasms, Prostate, Neoplasms, Prostatic, Prostate Cancer, Prostate Neoplasms, Prostatic Cancer | 06/14 | 06/14 | | |
NCT00901342: Open Label Study of Sipuleucel-T in Metastatic Prostate Cancer |
|
|
| Completed | 2 | 104 | US | sipuleucel-T, • Provenge® • APC8015 | Dendreon | Prostate Cancer | 12/14 | 06/15 | | |
NCT01431391: Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer |
|
|
| Completed | 2 | 68 | US | sipuleucel-T, PROVENGE®, APC8015, leuprolide acetate, Eligard® | Dendreon | Prostatic Neoplasm, Prostate Cancer, Prostatic Adenocarcinoma | 12/14 | 12/14 | | |
|
|
|
|
NCT01338012: Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer |
|
|
| Terminated | 2 | 8 | US | sipuleucel-T, PROVENGE, APC8015 | Dendreon | Prostate Cancer | 04/15 | 04/15 | | |
NCT02159950: Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer |
|
|
| Completed | 2 | 2 | US | Laboratory Biomarker Analysis, Sipuleucel-T, APC8015, APC8015 Vaccine, PA2024 (PAP/GM-CSF)-Loaded Dendritic Cell Vaccine, Provenge, Tasquinimod, ABR-215050, TASQ | Roswell Park Cancer Institute, Active Biotech AB | Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer | 07/15 | | | |
STAMP, NCT01487863: Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer |
|
|
| Completed | 2 | 69 | US | sipuleucel-T, PROVENGE(R), APC8015, abiraterone acetate, ZYTIGA(R) | Dendreon | Prostate Cancer Metastatic, Hormone Refractory Prostate Cancer, Castration-resistant Prostate Cancer | 05/16 | 06/16 | | |
|
|
|
STRIDE, NCT01981122: A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer |
|
|
| Completed | 2 | 52 | US | sipuleucel-T, PROVENGE(R), APC8015, enzalutamide, Xtandi | Dendreon | Metastatic Prostate Cancer | 06/17 | 06/17 | | |
|
